samedan logo
 
 
spacer
home > epc > winter 2002 > assessing study feasibility in the netherlands - a research site's point of view
PUBLICATIONS
European Pharmaceutical Contractor

Assessing Study Feasibility in the Netherlands - A Research Site's Point of View

Traditionally, sponsors have included feasibility checks in the process of choosing a study site. Sponsors often use standard feasibility forms for individual investigators as well as for SMO-type organisations. The ultimate goal of feasibility checking is to evaluate patient recruitment rate (in other words, number of patients to be randomised in a certain period) and to estimate costs.

In addition to the sponsor's validation of the research site, the site itself is responsible for undertaking a realistic and critical assessment of their resources and the type of study that is being offered, before deciding to accept the study for their research portfolio. The study's requirements and resources should also be assessed as accurately as possible from a regulatory point of view.

Regulation ICH 4.2 demands that an investigator should "be able to demonstrate a potential for recruiting the required number of suitable patients; to have sufficient time to properly conduct and complete the study within the agreed trial period and have an adequate, well informed staff with adequate facilities." When a site moves from participating in one study at a time to several studies simultaneously it has an impact on space, staff, patient recruitment systems and so on.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Henk Mulder, Director of Osteosupport BV

Dr Henk Mulder achieved his PhD in Internal Medicine and Endocrinology. He wrote his thesis 'Calcitonine concentration in blood in several disease states' in 1980 at the University of Amsterdam. After two decades of working as an Internist/Endocrinologist for the university hospital in Leiden and at a local hospital in Rotterdam, he founded the first European site management organisation named Good Clinical Practice (GCP). He participated in over 100 clinical trials as a Principal Investigator.

In early 2001 he left GCP and in June 2001 he founded Osteosupport - a hybrid company with integrated medical, paramedical and clinical trial activities. Osteosupport has been successfully involved in conducting three studies in the areas of arthritis, hypertension and male hormone replacement therapy.


spacer
Dr Henk Mulder
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

Small Scale Biomanufacturing – clinical trials, cell & gene therapies

18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol

This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >>

 
News and Press Releases

“PACK DIFFERENT” with EMBALLAGE 2008

“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement